SAN DIEGO--(BUSINESS WIRE)--ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that it intends to submit an NDA for ANX-530 (vinorelbine emulsion) by the end of 2009. The Company successfully completed the final manufacturing activities required for the NDA submission, which activities were re-started following the Company’s June 2009 equity financing.
